Regulatory
Sobi’s Gamifant (emapalumab) Receives FDA Approval for Primary Haemophagocytic Lymphohistiocytosis
Shots: The approval is based on P-II/III (NCT01818492) study results assessing Gamifant IV in patients with primary HLH, evaluating its safety, efficacy and tolerability The P-II/III study resulted in meeting […]readmore